SCHEMBL2656896

SCHEMBL2656896

CCCOC(C)c1ccc2c(c1)ncn2-c1cccc(-n2ccnc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 9/20 0.45
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP19A1 P11511 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SRC P12931 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
MAPK1 P28482 2/20 0.37
IDO1 P14902 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655096 0.92 SMN1; SMN2 (0.42) FGFR1SRCSMN1; SMN2MAPK1IDO1
SCHEMBL2653121 0.87 FGFR1 (0.43) FGFR1SRCIDO1HPGDALDH1A1
SCHEMBL2659620 0.87 FGFR1 (0.43) FGFR1CYP3A4SRCIDO1HPGD
SCHEMBL2662404 0.86 FGFR1 (0.38) FGFR1SRCSMN1; SMN2MAPK1IDO1
SCHEMBL2646511 0.84 HPGD (0.47) FGFR1CYP3A4CYP19A1SMN1; SMN2MAPK1
SCHEMBL2653789 0.82 IDO1 (0.42) FGFR1CYP3A4SRCSMN1; SMN2IDO1
SCHEMBL2653095 0.82 FGFR1 (0.47) FGFR1SRCSMN1; SMN2MAPK1HPGD
SCHEMBL2660553 0.80 FGFR1 (0.47) FGFR1CYP1A2CYP3A4CYP2D6CYP19A1
SCHEMBL2659773 0.80 FGFR1 (0.42) FGFR1SMN1; SMN2MAPK1IDO1GABRA1
SCHEMBL2659275 0.77 FGFR1 (0.39) FGFR1SRCIDO1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060069135-A1 Benzimidazole derivatives and their use for modulating the gaba-a receptor complex NEUROSEARCH A/S (DK) 2006-03-30 US claimed
US-20060069135-A1 Benzimidazole derivatives and their use for modulating the gaba-a receptor complex NEUROSEARCH A/S (DK) 2006-03-30 US disclosed
EP-1613618-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-01-11 EP disclosed
WO-2004087690-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069135-A1 Benzimidazole derivatives and their use for modulating the gaba-a receptor complex GABRB2, GABRB1, GABRB3 FGFR1 3374/4885CYP1A2 646/4885CYP3A4 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.